Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2017

01-11-2017 | Clinical trial

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

Authors: John V. Hegde, Xiaoyan Wang, Deanna J. Attai, Maggie L. DiNome, Amy Kusske, Anne C. Hoyt, Sara A. Hurvitz, Joanne B. Weidhaas, Michael L. Steinberg, Susan A. McCloskey

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Login to get access

Abstract

Purpose

For women with a personal history of breast cancer (PHBC), no validated mechanisms exist to calculate future contralateral breast cancer (CBC) risk. The Manchester risk stratification guidelines were developed to evaluate CBC risk in women with a PHBC, primarily for surgical decision making. This tool may be informative for the use of MRI screening, as CBC risk is an assumed consideration for high-risk surveillance.

Methods

Three hundred twenty-two women with a PHBC were treated with unilateral surgery within our multidisciplinary breast clinic. We calculated lifetime CBC risk using the Manchester tool, which incorporates age at diagnosis, family history, genetic mutation status, estrogen receptor positivity, and endocrine therapy use. Univariate and multivariate logistic regression analyses (UVA/MVA) were performed, evaluating whether CBC risk predicted MRI surveillance.

Results

For women with invasive disease undergoing MRI surveillance, 66% had low, 23% above-average, and 11% moderate/high risk for CBC. On MVA, previous mammography-occult breast cancer [odds ratio (OR) 18.95, p < 0.0001], endocrine therapy use (OR 3.89, p = 0.009), dense breast tissue (OR 3.69, p = 0.0007), mastectomy versus lumpectomy (OR 3.12, p = 0.0041), and CBC risk (OR 3.17 for every 10% increase, p = 0.0002) were associated with MRI surveillance. No pathologic factors increasing ipsilateral breast cancer recurrence were significant on MVA.

Conclusions

Although CBC risk predicted MRI surveillance, 89% with invasive disease undergoing MRI had <20% calculated CBC risk. Concerns related to future breast cancer detectability (dense breasts and/or previous mammography-occult disease) predominate decision making. Pathologic factors important for determining ipsilateral recurrence risk, aside from age, were not associated with MRI surveillance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schacht DV, Yamaguchi K, Lai J, Kulkarni K, Sennett CA, Abe H (2014) Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: results from screening breast MRI. AJR Am J Roentgenol 202(2):289–292. doi:10.2214/ajr.13.11553 CrossRefPubMed Schacht DV, Yamaguchi K, Lai J, Kulkarni K, Sennett CA, Abe H (2014) Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: results from screening breast MRI. AJR Am J Roentgenol 202(2):289–292. doi:10.​2214/​ajr.​13.​11553 CrossRefPubMed
3.
go back to reference de la Rochefordiere A, Mouret-Fourme E, Asselain B, Scholl SM, Campana F, Broet P, Fourquet A (1996) Metachronous contralateral breast cancer as first event of relapse. Int J Radiat Oncol Biol Phys 36(3):615–621CrossRefPubMed de la Rochefordiere A, Mouret-Fourme E, Asselain B, Scholl SM, Campana F, Broet P, Fourquet A (1996) Metachronous contralateral breast cancer as first event of relapse. Int J Radiat Oncol Biol Phys 36(3):615–621CrossRefPubMed
4.
go back to reference Kollias J, Evans AJ, Wilson AR, Ellis IO, Elston CW, Blamey RW (2000) Value of contralateral surveillance mammography for primary breast cancer follow-up. World J Surg 24(8):983–987 (discussion 988–989)CrossRefPubMed Kollias J, Evans AJ, Wilson AR, Ellis IO, Elston CW, Blamey RW (2000) Value of contralateral surveillance mammography for primary breast cancer follow-up. World J Surg 24(8):983–987 (discussion 988–989)CrossRefPubMed
8.
go back to reference Jacobson JA, Danforth DN, Cowan KH, d’Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P (1995) Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 332(14):907–911. doi:10.1056/nejm199504063321402 CrossRefPubMed Jacobson JA, Danforth DN, Cowan KH, d’Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P (1995) Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 332(14):907–911. doi:10.​1056/​nejm199504063321​402 CrossRefPubMed
10.
go back to reference Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. doi:10.1016/s0140-6736(11)61629-2 CrossRefPubMed Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. doi:10.​1016/​s0140-6736(11)61629-2 CrossRefPubMed
11.
go back to reference van Laar C, van der Sangen MJ, Poortmans PM, Nieuwenhuijzen GA, Roukema JA, Roumen RM, Tjan-Heijnen VC, Voogd AC (2013) Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer 49(15):3093–3101. doi:10.1016/j.ejca.2013.05.030 CrossRefPubMed van Laar C, van der Sangen MJ, Poortmans PM, Nieuwenhuijzen GA, Roukema JA, Roumen RM, Tjan-Heijnen VC, Voogd AC (2013) Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer 49(15):3093–3101. doi:10.​1016/​j.​ejca.​2013.​05.​030 CrossRefPubMed
12.
go back to reference Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679CrossRefPubMed Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679CrossRefPubMed
13.
go back to reference Sung JS, Stamler S, Brooks J, Kaplan J, Huang T, Dershaw DD, Lee CH, Morris EA, Comstock CE (2016) Breast cancers detected at screening MR imaging and mammography in patients at high risk: method of detection reflects tumor histopathologic results. Radiology 280(3):716–722. doi:10.1148/radiol.2016151419 CrossRefPubMedPubMedCentral Sung JS, Stamler S, Brooks J, Kaplan J, Huang T, Dershaw DD, Lee CH, Morris EA, Comstock CE (2016) Breast cancers detected at screening MR imaging and mammography in patients at high risk: method of detection reflects tumor histopathologic results. Radiology 280(3):716–722. doi:10.​1148/​radiol.​2016151419 CrossRefPubMedPubMedCentral
14.
go back to reference Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teule A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. doi:10.1007/s10549-016-3805-0 PubMedPubMedCentral Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teule A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. doi:10.​1007/​s10549-016-3805-0 PubMedPubMedCentral
15.
go back to reference Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM (2013) Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol 31(18):2282–2288. doi:10.1200/jco.2012.46.5732 CrossRefPubMed Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM (2013) Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol 31(18):2282–2288. doi:10.​1200/​jco.​2012.​46.​5732 CrossRefPubMed
16.
go back to reference Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89CrossRefPubMed Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89CrossRefPubMed
17.
go back to reference Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158CrossRefPubMedPubMedCentral Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158CrossRefPubMedPubMedCentral
18.
go back to reference Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM (2007) Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 147(7):441–450CrossRefPubMedPubMedCentral Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM (2007) Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 147(7):441–450CrossRefPubMedPubMedCentral
19.
go back to reference Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886CrossRefPubMed Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886CrossRefPubMed
20.
go back to reference Benichou J, Gail MH, Mulvihill JJ (1996) Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 14(1):103–110CrossRefPubMed Benichou J, Gail MH, Mulvihill JJ (1996) Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 14(1):103–110CrossRefPubMed
22.
go back to reference Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814CrossRefPubMedPubMedCentral Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814CrossRefPubMedPubMedCentral
24.
go back to reference Chiarelli AM, Prummel MV, Muradali D, Majpruz V, Horgan M, Carroll JC, Eisen A, Meschino WS, Shumak RS, Warner E, Rabeneck L (2014) Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol 32(21):2224–2230. doi:10.1200/jco.2013.52.8331 CrossRefPubMed Chiarelli AM, Prummel MV, Muradali D, Majpruz V, Horgan M, Carroll JC, Eisen A, Meschino WS, Shumak RS, Warner E, Rabeneck L (2014) Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol 32(21):2224–2230. doi:10.​1200/​jco.​2013.​52.​8331 CrossRefPubMed
28.
go back to reference Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, Geller BM, Abraham LA, Taplin SH, Dignan M, Cutter G, Ballard-Barbash R (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–175CrossRefPubMed Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, Geller BM, Abraham LA, Taplin SH, Dignan M, Cutter G, Ballard-Barbash R (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–175CrossRefPubMed
32.
33.
go back to reference Lehman CD, Lee JM, DeMartini WB, Hippe DS, Rendi MH, Kalish G, Porter P, Gralow J, Partridge SC (2016) Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst 108(3):djv349. doi:10.1093/jnci/djv349 CrossRefPubMed Lehman CD, Lee JM, DeMartini WB, Hippe DS, Rendi MH, Kalish G, Porter P, Gralow J, Partridge SC (2016) Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst 108(3):djv349. doi:10.​1093/​jnci/​djv349 CrossRefPubMed
Metadata
Title
Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer
Authors
John V. Hegde
Xiaoyan Wang
Deanna J. Attai
Maggie L. DiNome
Amy Kusske
Anne C. Hoyt
Sara A. Hurvitz
Joanne B. Weidhaas
Michael L. Steinberg
Susan A. McCloskey
Publication date
01-11-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4392-4

Other articles of this Issue 1/2017

Breast Cancer Research and Treatment 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine